Special Issue

Medicinal Cannabis: Advances in Therapeutics and Clinical Applications

Message from the Guest Editor

As cannabis products continue to proliferate in medicinal and recreational markets, this Special Issue of Biomedicines will focus on recent updates related to the product formulation, therapeutic applications, and safety of cannabis products. Submissions are welcome on the following topics: (1) Pharmacology and mechanism of action; research elucidating the molecular mechanisms of cannabinoids, terpenes, and other bioactive cannabis compounds; discovery of biomarkers useful for indicating cannabis-associated health effects: pharmacokinetic and pharmacodynamic studies of cannabis-based treatments. (2) Clinical applications: clinical trial data on the use of cannabis to treat health conditions; the role of cannabis in special populations (pediatric, geriatric). (3) Advancements in cannabis-based pharmaceuticals: innovations in formulations, delivery systems, and development of cannabis-based medicines. (4) Safety: studies assessing the safety of cannabis formulations with special focus on long-term usage and drug interaction potential.

Guest Editor

Dr. Erin Berthold

 Planted in Science Consulting, LLC, St Augustine, FL 32080, USA
 PhD in Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/233191

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).